QX030N

Caldera Therapeutics announced its launch on Wednesday as well as the dosing of the first participants in a Phase I trial of its lead programme, a bispecific antibody that targets the IL-23p19 and TL1A pathways for inflammatory bowel disease (IBD) and other immunologic and inflammatory conditions. "By elegantly combining two powerful autoimmune targets in a single molecule, CLD-423 represents the next frontier in IBD treatment," said CEO Praveen Tipirneni, who formerly led Morphic Therapeutic, a company Eli Lilly acquired for $3.2 billion in 2024 to get its hands on IBD candidate MORF-057, a selective oral small-molecule inhibitor of α4β7 integrin. "Bispecifics have the potential to redefine the efficacy bar in IBD, and CLD-423 is rationally designed to achieve a best-in-disease profile with optimised efficacy, safety, pharmacokinetics and developability," remarked Tipirneni.Caldera was formed in 2025, raising $75 million via a series A round last April from Atlas Venture, LAV and venBio. The company said Wednesday that it has since completed a further $37.5-million series A-1 round led by Omega Funds, with participation from new investors Wellington Management and Janus Henderson Investors.The latest investment will fund ongoing clinical development of CLD-423. Caldera in-licensed it from Chinese biotech Qyuns Therapeutics, which designates the compound as QX030N.